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abstract
 
We characterized the functional and molecular properties of nicotinic acetylcholine receptors
(AChRs) expressed by IMR-32, a human neuroblastoma cell line, and compared them to human 
 
 
 
3 AChRs ex-
pressed in stably transfected human embryonic kidney (HEK) cells. IMR-32 cells, like neurons of autonomic gan-
glia, have been shown to express 
 
 
 
3, 
 
 
 
5, 
 
 
 
7, 
 
 
 
2, and 
 
 
 
4 AChR subunits. From these subunits, several types of 
 
 
 
3
AChRs as well as homomeric 
 
 
 
7 AChRs could be formed. However, as we show, the properties of functional AChRs
in these cells overwhelmingly reﬂect 
 
 
 
3
 
 
 
4 AChRs. 
 
 
 
7 AChR function was not detected, yet we estimate that there
are 70% as many surface 
 
 
 
7 AChRs in IMR-32 when compared with 
 
 
 
3 AChRs. Agonist potencies (EC
 
50
 
 values) fol-
lowed the rank order of 1,1-dimethyl-4-phenylpiperazinium (DMPP; 16
 
 
 
1 
 
 
 
M) 
 
 
 
 nicotine (Nic; 48
 
   
 
7 
 
 
 
M) 
 
 
 
cytisine (Cyt; 57
 
   
 
3 
 
 
 
M) 
 
 
 
 acetylcholine (ACh; 59
 
   
 
6 
 
 
 
M). All agonists exhibited efﬁcacies of at least 80% rela-
tive to ACh. The currents showed strong inward rectiﬁcation and desensitized at a rate of 3 s
 
 
 
1
 
 (300 
 
 
 
M ACh; 
 
 
 
60
mV). Assays that used mAbs conﬁrmed the predominance of 
 
 
 
3- and 
 
 
 
4-containing AChRs in IMR-32 cells. Al-
though 18% of total 
 
 
 
3 AChRs contained 
 
 
 
2 subunits, no 
 
 
 
2 subunit was detected on the cell surface. Chronic Nic
incubation increased the amount of total, but not surface 
 
 
 
3
 
 
 
2 AChRs in IMR-32 cells. Nic incubation and re-
duced culture temperature increased total and surface AChRs in 
 
 
 
3
 
 
 
2 transfected HEK cells. Characterization of
various 
 
 
 
3 AChRs expressed in HEK cell lines revealed that the functional properties of the 
 
 
 
3
 
 
 
4 cell line best
matched those found for IMR-32 cells. The rank order of agonist potencies (EC
 
50
 
 values) for this line was DMPP
(14
 
   
 
1 
 
 
 
M) 
 
 
 
 Cyt (18
 
   
 
1 
 
 
 
M) 
 
 
 
 Nic (56
 
   
 
15 
 
 
 
M 
 
 
 
 ACh (79
 
   
 
8 
 
 
 
M). The efﬁcacies of both Cyt and DMPP
were 
 
 
 
80% when compared with ACh and the desensitization rate was 2 s
 
 
 
1
 
. These data show that even with the
potential to express several human nicotinic AChR subtypes, the functional properties of AChRs expressed by
IMR-32 are completely attributable to 
 
 
 
3
 
 
 
4 AChRs.
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INTRODUCTION
 
 
 
3 acetylcholine receptors (AChRs)* have been identi-
ﬁed as the predominant neuronal AChR in ganglia of
the autonomic nervous system (Sargent, 1993; McGe-
hee and Role, 1995). Most ganglionic neurons express a
repertoire of nicotinic subunits that typically includes
 
 
 
3, 
 
 
 
5, 
 
 
 
7, 
 
 
 
2, and 
 
 
 
4. Much evidence suggests that the
 
 
 
3 AChR is the main mediator of the nicotinic postsyn-
aptic response in autonomic ganglia (Covernton et al.,
1994; Mandelzys et al., 1994; Rust et al., 1994). Knock-
out mice that lack 
 
 
 
3 subunits illustrate the critical role
played by these AChRs in the peripheral nervous sys-
tem. These animals have increased perinatal mortality
and exhibit severe physiologic impairment in organs in-
nervated by the autonomic nervous system (Xu et al.,
1999a). 
 
 
 
7 AChRs are expressed widely in ganglia, also.
Selective inhibition of 
 
 
 
3 AChRs failed to block synaptic
transmission in chick ciliary ganglion showing that 
 
 
 
7
AChRs are sufﬁcient to sustain transmission in this
preparation (Ullian et al., 1997). Knockout mice lack-
ing 
 
 
 
7 AChRs had normal nervous system development
(Orr-Urtreger et al., 1997), but exhibited impaired hy-
potensive reﬂex tachycardia (Franceschini et al., 2000).
Since the loss of 
 
 
 
3 function in mice is lethal largely due
to autonomic dysfunction, the inability of 
 
 
 
7 AChRs to
sustain adequate function brings into question its spe-
cialized role in the autonomic nervous system.
Knockout mice that lack both 
 
 
 
2 and 
 
 
 
4 subunits are
similar in phenotype to the 
 
 
 
3 knockout animals (Xu
et al., 1999b). Mice that lacked only the 
 
 
 
4 subunit sur-
vived but exhibited profound reduction in nicotine
(Nic)-induced whole-cell currents in superior cervical
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ganglion. These animals maintained sufﬁcient auto-
nomic function, presumably, through 
 
 
 
2 subunit re-
dundancy or compensation. Mice lacking the 
 
 
 
2 sub-
unit had apparently normal organ function and nor-
mal whole-cell currents in superior cervical ganglion.
Even after these elaborate genetic perturbations, many
questions remain regarding nicotinic signaling within
the autonomic nervous system. In particular, to what
extent does 
 
 
 
3
 
 
 
2, 
 
 
 
3
 
 
 
4, or 
 
 
 
7 AChRs normally con-
tribute to ganglionic transmission, and what other roles
do they have? A better understanding of the functional
properties of these AChRs as well as how AChR expres-
sion might be regulated will help to clarify these issues.
IMR-32 cells provide a useful model with which to study
the subunit composition of human ganglionic AChRs
as they express the characteristic complement of “gan-
glionic” AChR subunits. Additionally, we have devel-
oped a series of cell lines that express 
 
 
 
3 AChRs
formed from combinations of these ganglionic sub-
units. We determined and then compared the func-
tional properties of recombinant AChRs with “native”
AChRs that are expressed by IMR-32 cells. We use func-
tional and pharmacological proﬁling to investigate fur-
ther the subunit composition of human AChRs ex-
pressed by IMR-32 cells and support our conclusions
with various antibody-based molecular techniques.
 
MATERIALS AND METHODS
 
Tissue Culture
 
Transfected human embryonic kidney (HEK) tsA201 cells were
maintained in DME medium as described previously (Wang et
al., 1998). Cytotoxic selection antibiotics were added to the me-
dia to ensure integrity of AChR subunit expression. 0.5 mg/ml
Zeocin (Invitrogen) was used for 
 
 
 
3 subunit expression, 0.6 mg/
ml G-418 (Life Technologies) was used for 
 
 
 
2 or 
 
 
 
4 subunit se-
lection, and 0.2 mg/ml hygromycin B (Boehringer Mannheim)
was used for 
 
 
 
5 subunit selection. IMR-32 neuroblastoma cells
(Tumilowicz et al., 1970) were obtained from American Tissue
Culture Collection and SH-SY5Y neuroblastoma cells (Ross et al.,
1983) were provided by June Biedler and Barbara Spengler
of Sloan Kettering Institute for Cancer Research. Both were
maintained in media consisting of a 1:1 mixture of HAMs F-12
(Sigma-Aldrich) and Eagle’s minimum essential medium (Sigma-
Aldrich) with penicillin (100 U/ml) and streptomycin (100 
 
 
 
g/
ml; Life Technologies) and 10% FBS (Hyclone).
 
Electrophysiology
 
At least 2 d before recording, HEK cells were plated onto glass cov-
erslips coated with rat tail collagen (Type 1; Collaborative Biomed-
ical Products), and the IMR-32 cells were plated onto glass cov-
erslips coated with mouse laminin (Collaborative Biomedical
Products). Currents were measured by standard patch-clamp
techniques (Hamill et al., 1981). Agonist-containing solutions
were applied to the cells by gravity fed fused glass tubing that was
connected to multiple reservoirs mounted above the recording
chamber. The recording solution contained the following (in
mM): 150 NaCl, 5 KCl, 1 MgCl
 
2
 
, 2 CaCl
 
2
 
, 5 HEPES, and was ad-
justed to pH 7.3 with NaOH. Electrodes (5–8 M
 
 
 
) were formed
from borosilicate glass and were ﬁlled with a solution containing
the following (in mM): 150 cesium gluconate, 10 Cs-EGTA, and 10
HEPES, adjusted to pH 7.2 with CsOH. Cell access resistances
were typically 8–15 M
 
 
 
 and were compensated (40–60%) when
peak currents were in excess of 2 nA. Cells transfected with 
 
 
 
3
 
 
 
2
or 
 
 
 
3
 
 
 
5
 
 
 
2 AChRs were treated for 12 h with Nic (100 
 
 
 
M) fol-
lowed by a minimum of 1-h wash with normal media before re-
cording (Wang et al., 1998) or were incubated overnight at 29
 
 
 
C
to increase the levels of functional AChRs. Currents were activated
and recorded as described previously (Wang et al., 1998). Concen-
tration–response curves were constructed and ﬁtted to the follow-
ing logistic equation in Origin (Ver. 4.1; Microcal Software, Inc.):
where 
 
y
 
 is the normalized response amplitude, 
 
A
 
1
 
 is the maximum
amplitude asymptote of the ﬁt, 
 
A
 
2
 
 is the minimum asymptote of
the ﬁt, 
 
x
 
 is the concentration of agonist, 
 
x
 
0
 
 is the EC
 
50
 
 value, and
 
 p
 
is the steepness of the ﬁtted curve. In some cases, the concentra-
tion–response relationship would peak and then decline with in-
creasing concentrations of agonist. In the cases where the decline
caused an obviously inferior ﬁt, the reduced amplitude responses
at higher concentrations were not included in the ﬁt. Desensitiza-
tion time constants were determined by ﬁtting exponential equa-
tions to the data. Representative traces were constructed by open-
ing data ﬁles in Axograph 3.55 (Axon Instruments) and export-
ing data to Canvas 5.0 (Deneba Software, Inc.).
Single-Channel Analysis
Single-channel currents were recorded and analyzed as described
previously (Nelson and Lindstrom, 1999). In brief, channel activity
was recorded in outside-out conﬁguration patches by isolating the
patch in a stream of ACh (1–5  M). Recordings were performed in
ND-96 saline also containing 50 mM dextrose, as used previously to
characterize single-channel properties for AChRs expressed by
IMR-32 cells (Nelson and Lindstrom, 1999). Data were sampled
ofﬂine at 10 kHz (model Axoscope 2.0; Axon Instruments) and ﬁl-
tered at 3 kHz (model 902; 8-pole Bessel,  3 dB; Frequency De-
vices, Inc.) for analysis. All single-channel analysis and ﬁtting were
performed with pClamp 6.0.3 (Axon Instruments).
Production of mAb 337
mAb 337 (mouse IgG) was developed from a bacterially ex-
pressed fusion protein consisting of the large cytoplasmic loop
located between the M3 and M4 transmembrane domains of the
human  4 subunit (amino acids 305–419) coupled at the NH2
terminus to bacterial glutathione S-transferase (Wang et al.,
1998). Mice were immunized with the fusion protein puriﬁed
from bacterial inclusion bodies. The animals were boosted four
times over several months while titers were monitored by test
bleeds against human  3 4 AChRs (from transfected HEK cells)
in immunoprecipitation assays. 5 d after a ﬁnal boost with anti-
gen, the animal with the highest titers was killed. Hybridomas for
mAb production were formed by fusion of the animal’s splenic
lymphocytes with Sp2 myeloma cells according to a procedure
adapted from (Lane et al., 1986). Wells containing hybridomas
were then screened against human  3 4 AChRs by immunopre-
cipitation assays and positive wells were cloned. As we show here,
in addition to recognizing the  4 subunit in its native conﬁrma-
tion, the antibody also recognizes the denatured subunit as well.
Lack of cross-reactivity with human  3,  5, or  2 subunits was es-
tablished using AChRs extracted from the  3 5 2 cell line with
mAb 337-coated microwells using the procedure described below
for radioimmune assays. All animals were handled in accordance
with guidelines set forth by the Institutional Animal Care and
y
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Use Committee (IACUC) at the University of Pennsylvania under
approved protocol on ﬁle with that ofﬁce. IACUC operates un-
der an institutional Animal Welfare Assurance (A3079-01) on ﬁle
with the Ofﬁce for Protection from Research Risks at the Na-
tional Institutes of Health.
Radioimmune Assays (RIAs)
IMR-32 and SH-SY5Y cells were grown as described above until
just before conﬂuence in T-175 (175 cm2) tissue culture ﬂasks
(model Falcon 3112; Becton Dickinson) then detached with 5
mM EDTA in PBS, pelleted by centrifugation, and used immedi-
ately or frozen after removal of media. Fresh or frozen IMR-32
cells were suspended and triturated in a 2% Triton X-100 in
buffer A (50 mM Na2HPO4-NaH2PO4, pH 7.5, 50 mM NaCl, 5
mM EDTA, 5 mM EGTA, 5 mM benzamidine, 15 mM iodoacet-
amide, and 2 mM phenylmethylsulfonyl ﬂuoride at a 3:1–6:1 ratio
(buffer volume/cell volume) and placed on a rotating mixer for
2–3 h at 4 C. Cellular debris was removed by centrifugation and
supernatant extract was collected.
For solid phase RIA, AChRs solubilized in Triton were incu-
bated in Immulon 4 microwells (Dynatech Laboratories) coated
with mAb 210 (speciﬁc for  3 and  5 AChRs; Wang et al., 1996),
mAb 295 (speciﬁc for  2 AChRs; Whiting and Lindstrom, 1988),
or mAb 337 (speciﬁc for  4 AChRs) overnight at 4 C. The label-
ing of bound AChRs was carried out by including a supersaturat-
ing concentration of 10 nM [3H]epibatidine during the incuba-
tion in the wells. Unbound material was removed from wells by
washing three times with ice-cold 0.5% Triton in PBS. The re-
maining contents of the wells were stripped with 75  l of 2.5%
SDS containing 5%  -mercaptoethanol and then transferred to
liquid scintillation tubes containing 3 ml of Optiphase “Hisafe” 3
scintillation ﬂuid (Fisher Scientiﬁc). The amount of bound
[3H]epibatidine was determined by liquid scintillation counting
for 5 min using a liquid scintillation counter (model Wallac 1410;
Perkin-Elmer Wallac). Background was determined using wells
coated with BSA or goat anti–rat IgG (GART).
To measure the amount of  3-containing AChRs that could be
labeled in intact cells by [3H]epibatidine, IMR-32 cells were
plated in 35-mm tissue culture dishes and grown until conﬂuent.
At this time, the media was replaced with 0.5 ml of media that
contained 2 nM [3H]epibatidine and returned to the tissue cul-
ture incubator. For background determinations, 300  M Nic was
added 45 min before [3H]epibatidine. After 2 h at 37 C, the me-
dium was then removed and the cells quickly rinsed with PBS.
The cells were removed from the dishes by trituration with 0.5 ml
buffer A, and then lysed with an ultrasonic cell disrupter (model
Soniﬁer 200; Branson Ultrasonics Corp.). Membrane fragments
were collected on glass ﬁber ﬁlters (model GF/F; Whatman; 25
mm, treated with 0.3% polyethylenimine) followed by four rapid
1-ml washes with ice cold PBS. Filters were then transferred to
scintillation tubes for counting of retained [3H]epibatidine.
For isolation and measurement of  7-containing AChRs, mi-
crowells were coated with a combination of mAbs 306 and 319
that recognizes human  7 subunits (Peng et al., 1994). Cell ex-
tracts were prepared as described above and aliquots were incu-
bated in mAb-coated wells overnight at 4 C with 125I- -BGT (20
nM; 0.48 Ci/ mol). For background determinations, unlabeled
 -BGT (200 nM) was included in the incubation 1 h before addi-
tion of 125I- -BGT. After overnight incubation, unbound material
was removed as described above and the amount of bound 125I-
 -BGT was determined by gamma counting.
Surface AChR Labeling
To measure surface AChRs, cells were collected from tissue cul-
ture ﬂasks and gently pelleted by centrifugation followed by a
wash in normal culture medium containing 10% FBS. Cells were
resuspended in tissue culture medium and aliquoted (500  l)
into microcentrifuge tubes. Surface  3-containing AChRs were
labeled by incubation (2–4 h) with 125I-mAb 210 (4 nM; 0.46 Ci/
 mol) and surface  2-containing AChRs were labeled with
125I-mAb 295 (4–6 nM; 0.69 Ci/ mol). Background determina-
tions were made in parallel by including at least 50-fold excess
unlabeled mAb in a 1 h preincubation to block speciﬁc sites. In-
cubations were carried out at 37 C with constant mixing. After in-
cubation, cells were diluted with an equal volume of tissue cul-
ture media, pelleted, and then washed twice more with clean me-
dia. Amount of bound 125I-mAb was then determined by gamma
counting.
Western Blotting
Triton X-100 extraction of AChRs from IMR-32 and SH-SY5Y
neuroblastoma cells were performed as described above. The ex-
tracts were incubated overnight at 4 C with mAb-coupled agarose
to select and concentrate AChRs. AChRs were isolated using acti-
vated CH Sepharose 4B resin (Amersham Pharmacia Biotech)
coupled with mAb 210 for  3 AChRs, coupled with mAb 295 for
 2 AChRs, or coupled with mAb 337 for  4 AChRs (all at 2 mg
mAb/ml of resin). After incubation, bound AChRs were eluted
using 3% SDS sample buffer without reducing agents. The sam-
ples were loaded on 12% polyacrylamide gels containing SDS
and electrophoresed. Transfer of the proteins was done in a
semi-dry electroblotting chamber (Semi-Phor; Hoefer Scientiﬁc
Instruments) to Trans-Blot® medium PVDF membrane (Bio-
Rad). The blot membranes were then quenched for 1 h at room
temperature with 5% dried milk in PBS containing 0.5% Tween
20 and 10 mM NaN3 (PBS/Tween) with constant agitation. Anti-
sera against  3 or  2 subunits (Kuryatov et al., 2000) were then
added at 1:200 dilution and incubated overnight at 4 C. After
three washes with PBS/Tween, labeling was done by the addition
of 125I-GART antibodies (2 nM, 0.81 Ci/ mol) for 3 h at room
temperature, followed by a brief rinse and three washes (10 min
each) with PBS/Tween. 125I-mAb 337 (2 nM, 0.83 Ci/ mol) was
used to identify the  4 subunit in which case the primary label-
ing was followed by the wash steps with PBS/Tween. Autoradiog-
raphy was performed at  80 C with exposures between 10 min
and overnight using Kodak Biomax® MS ﬁlm and intensifying
screen.
Immunoﬂuorescence with Confocal Microscopy
IMR-32 or permanently transfected cells were plated on either
laminin-coated or collagen-coated glass coverslips, respec-
tively, and ﬁxed with 10% formalin/PBS for 1 h at room tem-
perature for labeling with ﬂuorescent antibody to track the
presence of AChR subunit proteins. Fixed cells were then
washed three times with PBS to remove ﬁxative. Attachment of
ﬂuorophores to primary antibodies was done using a kit (Mo-
lecular Probes) to attach either Alexa ﬂuor 488 or 594 to the
antibodies. Primary labeling with unlabeled antibody was per-
formed overnight at 4 C in PBS containing antibody with 5%
goat serum. Secondary labeling was carried out after washing
three times with PBS to remove the unbound primary anti-
body, followed by Alexa ﬂuor 594-labeled GART (Molecular
Probes) for mAb 295 or Alexa ﬂuor 568-labeled goat anti–
mouse (GAM) IgG (Molecular Probes) for mAb 337. Second-
ary antibodies were used at ﬁnal concentrations of 4  g/ml
for GART or 3  g/ml for GAM, and were applied for 3–4 h at
room temperature in the presence of 5% goat serum. After
washing three times with PBS, primary labeled mAb 210 (Al-
exa ﬂuor 488) was applied overnight at 4 C at a ﬁnal concen-
tration of 5  g/ml in the presence of 5% normal rat serum.566 Human Ganglionic AChRs
To access intracellular AChR subunits, cells were permeabi-
lized with 0.5% Triton X-100 for 1 h at room temperature be-
fore labeling with antibodies. To-Pro 3 iodide (Molecular
Probes) was included as a nuclear counterstain at 0.5–1  M
for 20–60 min. Coverslips with labeled cells were rinsed twice
with PBS and once with deionized water, then mounted on
slides using Pro-Long antifade (Molecular Probes), dried, and
stored at 4 C until viewed. Images of labeled cells were then
acquired using a Leica TCS 4 D laser scanning confocal micro-
scope.
RESULTS
Pharmacological Properties of Functional AChRs in 
IMR-32 Cells
Rapid application of nicotinic agonists to patch-
clamped IMR-32 cells evoked responses ranging up to
several hundred picoamps when clamped at  60 mV.
An example of a concentration/response family of cur-
rents from a cell is shown in Fig. 1A using Cyt. The con-
Figure 1. Functional and pharmacological properties of AChRs expressed by the human neuroblastoma cell line IMR-32. (A) A family
of currents recorded in response to increasing concentrations of Cyt for a cell clamped at  60 mV. In the inset, the scaled response of this
cell to a maximally effective concentration of Cyt (300  M) is shown relative to the response to ACh (300  M) which was chosen to deﬁne
agonist efﬁcacy. (B). The full concentration/response relationships are shown for ACh ( ), Nic ( ), Cyt ( ), and DMPP ( ). With the
exception of DMPP, all agonists had similar potencies. The EC50 values were 66   5  M for ACh, 48   8  M for Nic, 57   3  M for Cyt,
and 16   1  M for DMPP. The relatively high efﬁcacy of Cyt and the relatively high potency of DMPP were the most distinguishing phar-
macological properties found for the IMR-32 AChR response. (C). The current/voltage relationship for IMR-32 cells recorded in response
to application of 100  M ACh. The currents were no longer inward at  0 mV, which was consistent with a nonselective cation channel.
The currents exhibited strong inward rectiﬁcation, but when depolarized beyond  60 mV, outward currents were observed. (D). Repre-
sentative recording and exponential ﬁt of the current decay for IMR-32 cells.567 Nelson et al. 
centration/response relationships are shown for ACh,
Nic, DMPP, and Cyt along with the curve ﬁts used to de-
termine the EC50 values (Fig. 1 B). The rank order of
potency was DMPP   Nic   Cyt   ACh. This rank or-
der provided a proﬁle for functional native AChR(s)
present in IMR-32 cells for comparison with agonist
proﬁles for AChRs of deﬁned composition expressed in
transfected cells as described below.
All of the agonists exhibited nearly full efﬁcacy (i.e.,
 80%) with respect to ACh. The maximum responses
to ACh and Cyt are shown for the cell in Fig. 1 A to il-
lustrate the efﬁcacy of Cyt, which was similar to that of
Nic and slightly greater than the efﬁcacy of DMPP. At
high agonist concentrations, “rebound” currents were
frequently observed, and the peak current amplitudes
were often reduced compared with lower agonist con-
centrations. This was especially true for DMPP. This ef-
fect was likely the result of channel block by the agonist
and the rebound current occurred as the channel
block was relieved on washout.
Functional Properties of IMR-32 AChRs
The current-voltage relationship for ACh-activated cur-
rents from IMR-32 cells were studied between  120 and
 80 mV (Fig. 1 C). The currents approached reversal
when the holding potential was between  10 and 0 mV,
which is expected for nonselective cation channels un-
der these recording conditions. Additionally, strong in-
ward rectiﬁcation was found at positive holding poten-
tials until  60 mV, where some reversal was observed.
Desensitization of currents recorded from IMR-32
cells was usually best described by a single exponential
function which could be ﬁt with a time constant of de-
cay of     368   94 ms (n   8) (Fig. 1 D). In some
cases, the desensitization was ﬁt best by a double expo-
nential function with time constants of 73   27 ms and
550   136 ms (n   2). In addition to desensitization
during the application of agonist, the peak amplitude
of the currents decreased slightly over the course of a
full concentration/response experiment. This “run-
down” was not prevented by inclusion of various agents
in the recording electrode such as ATP, creatine phos-
phokinase, phosphocreatine, and magnesium, or vari-
ous combinations of these substances. Additionally, us-
ing a recording solution that was based on CsCl also
did not prevent the rundown (unpublished data).
Effects of Nicotinic Antagonists on IMR-32 Currents
Responses to 100  M ACh were antagonized by coappli-
cation of the antagonists d-tubocurare, mecamylamine,
and hexamethonium with IC50 values of 0.4   0.2, 3.2  
0.6, and 8.5   3.0  M, respectively (Fig. 2 A). The revers-
Figure 2. Antagonist sensitivity of the AChR currents activated in IMR-32 cells. (A) The concentration response relationship is shown for d-
tubocurare (d-TC;  ), mecamylamine (Mec;  ), and hexamethonium (C-6;  ) on IMR-32 cells with IC50 values of 0.4   0.2, 3.2   0.6, and
8.5   3.0  M, respectively. All drugs were coapplied with 100  M ACh at a holding potential of  60 mV. The peak amplitudes of the resulting
currents were then plotted against concentration of the antagonist after normalizing to the peak amplitude of the current recorded in the ab-
sence of any antagonist. All three drugs completely blocked the currents at higher concentrations. (B) Representative currents are shown for
testing the sensitivity of IMR-32 AChR currents to the reversible  7 selective antagonist MLA (20 nM). No inhibition was observed, which was
consistent with the idea that the macroscopic current recorded in the cells reﬂects predominately the activity of  3 AChRs.568 Human Ganglionic AChRs
ible  7 selective antagonist, methyllycaconitine (MLA),
had no effect on Nic-activated (300  M) currents when
applied at 20 nM with a 10 min preincubation (Fig. 2 B).
This concentration of MLA (20 nM) was almost three
orders of magnitude higher than the IC50 reported for
homomeric  7 AChRs (Palma et al., 1996) or  7 con-
taining AChRs in rat hippocampal neurons (Alkondon
et al., 1992). The lack of antagonism by MLA was con-
sistent with the fact that the currents lacked the rapid
desensitization that is a hallmark property of  7 AChRs.
To validate the ability of our application system to acti-
vate  7 AChRs efﬁciently before they desensitized, we
recorded the rapidly desensitizing Nic-activated cur-
rents that have been attributed to  7 AChRs from rat
hippocampal neurons (unpublished data). Thus, it was
concluded that any contribution of  7 AChRs to mac-
roscopic currents from IMR-32 cells was negligible.
Agonist Potencies and Efﬁcacies in Permanently Transfected 
 3 AChR Cell Lines
As reported previously (Wang et al., 1998), HEK tsA201
cells stably transfected with combinations of AChR sub-
units that are commonly expressed in ganglionic neu-
rons (i.e.,  3,  5,  2, and  4 subunits) responded ro-
bustly to nicotinic agonists. Peak currents ranged up to
15 nA when clamped at  60 mV. Here, we present a
more thorough functional characterization of these
cell lines so that we can compare, under like condi-
tions, the properties of AChRs with known subunit
composition to the properties IMR-32 AChRs as de-
scribed above. Examples of currents activated by ACh
(300  M) or Cyt (300  M) from each cell type ( 3 4,
 3 2,  3 4 5, and  3 2 5) are shown in Fig. 3. For
 3 4 transfected cells, the agonist potency rank order
was DMPP   Cyt   Nic   ACh, with EC50 values rang-
Figure 3. Efﬁcacy of Cyt on  3 AChRs expressed by permanently transfected HEK cells is determined by whether the AChR contains a  2
or  4 subunit. Representative currents are shown for permanently transfected cell lines that express  3 2,  3 2 5,  3 4, and  3 4 5
AChRs. For each cell, a pair of currents are superimposed that reﬂect current activated by a near saturating (300  M) concentration of
ACh and a maximally effective concentration (300  M) of Cyt. Clearly, the efﬁcacy of Cyt relative to ACh in the cell lines that express the  2
subunit is far lower (5% or less) than that found for the cell lines that express the  4 subunit ( 80% or more).569 Nelson et al. 
ing from 15  M for DMPP to 79  M for ACh (Fig. 4).
Cyt exhibited 60% efﬁcacy, whereas DMPP had 50% ef-
ﬁcacy and Nic had  85% efﬁcacy (Fig. 4).
The  3 2 and  3 5 2 cell lines expressed few sur-
face AChRs unless the cells were incubated in Nic
(Wang et al., 1998). Therefore, before performing
functional studies, these cells were incubated overnight
with 100  M Nic. The medium was exchanged to re-
move the Nic at least 1 h before recording. The agonist
sensitivity proﬁle for  3 2 AChRs was markedly differ-
Figure 4. Concentration-response relationships for nicotinic agonists on  3 AChRs in permanently transfected HEK cells establish potency
and efﬁcacy proﬁles that allow for distinguishing  2 and  4 containing AChRs. Each panel depicts the concentration-response relationship
for the indicated permanently transfected  3 cell line. The symbols reﬂect correspond to different agonists as follows: ACh ( ), Nic ( ), Cyt
( ), and DMPP ( ). The EC50 values are shown in Table I. Each point in the ﬁgure represents the peak amplitude of the current evoked by
that concentration of agonist normalized to the peak amplitude of the current evoked by 300  M ACh in the same cell. The cells were
clamped at  60 mV for  3 2 and  3 5 2 and at  30 mV for  3 4 and  3 5 4 cell lines.  4 AChRs were more sensitive to activation by
ACh, whereas  2 AChRs were slightly more sensitive to activation by DMPP. Cyt had virtually no efﬁcacy in activating  2 AChRs, whereas it had
 50% efﬁcacy on  4 AChRs. DMPP exhibited efﬁcacy that was equal to, or higher than ACh on  2 AChRs, but it was  50% efﬁcacious on  4
AChRs. Nic was poor in distinguishing between  2 and  4 AChRs. The data for ACh and Nic are taken from Wang et al. (1998).570 Human Ganglionic AChRs
ent from that for  3 4 AChRs, with the rank order of
potency DMPP   Cyt   Nic   ACh, which reﬂected
EC50 values that ranged from 9  M for DMPP to 209
 M for ACh. Consistent with previous studies of  3 2
AChRs (Papke and Heinemann, 1994), the efﬁcacy of
Cyt was extremely poor (5%) on  3 2 AChRs (Figs. 3
and 4). This was in contrast to the much higher efﬁcacy
of Cyt on the  3 4 (75%),  3 4 5 (75%), or IMR-32
(80%) cell lines. In addition, DMPP exhibited efﬁcacy
greater than ACh. Thus, agonist efﬁcacies for Cyt and
DMPP relative to ACh are useful in predicting the pres-
ence of the  2 subunit in native  3 AChRs.
Reduced Temperature Increases Functional  3 2 AChRs
When incubated at reduced temperature (29 C) over-
night,  3 2 cells increased their amount of functional
AChRs as judged by the gain of responsiveness to ag-
onist, much like when the cells were incubated in
Figure 5. Culturing the  3 2 AChR cell line at 29 C increases the population of functional AChRs similar to overnight incubation in
Nic. (A) A family of representative currents is shown for the concentration-response relationship for  3 2 cells that were placed at 29 C
for at least 6 h and as long as 48 h. For comparison, currents recorded from cells that were incubated in Nic (100  M) overnight are also
shown (Wang et al., 1998). (B) The sensitivity to activation by ACh for the cells grown at reduced temperature were identical to those that
had been incubated overnight in 100  M Nic. The full concentration/response for both conditions is also shown. Responses were normal-
ized to the response peak measured for 300  M ACh for each cell. The EC50 for each condition was 202   14  M for cells grown at 29 C
( ) and was 209   26  M for cells incubated overnight in Nic ( ). (C) Representative currents are shown for IMR-32 cells that were incu-
bated overnight in Nic (100  M). The responses to 300  M ACh and 300  M Cyt are nearly identical to currents recorded from naive
IMR-32 cells (Fig. 1 A, inset).571 Nelson et al. 
Nic overnight (Wang et al., 1998). The temperature-
induced AChR increase was similar to a recent report
for  4 2 AChRs expressed in HEK cells (Cooper et al.,
1999). Since our functional studies with  3 2 or
 3 5 2 AChRs required exposure to Nic before re-
cording, we were unable to determine if the agonist ex-
posure itself altered functionality when compared with
naive AChRs. However, the temperature-induced in-
crease in AChRs allowed us to characterize  3 2
AChRs without prior exposure to Nic (Fig. 5 A). The
EC50 value for cells incubated at 29 C was 202   14  M,
which compares well to the EC50 of 209   26  M for
cells incubated in Nic (Fig. 5 B). Since the functional
properties were the same regardless of treatment, it
seems unlikely that Nic-treated  3 2 AChRs have prop-
erties that differ from  3 2 AChRs that have not been
Nic-treated. Previous studies with  3 2 AChRs ex-
pressed in Xenopus oocytes showed that this Nic treat-
ment did not alter the functional properties of the
AChR (Wang et al., 1998). By contrast with the Nic-in-
duced increase in surface  3 2 AChRs in the trans-
fected cell line that was reﬂected by the appearance of
substantial electrophysiological responses, overnight
incubation of IMR-32 cells in Nic did not increase the
amount of  3 2 AChRs on the surface of these cells
(see last paragraph of Subunit Content of AChRs...) or al-
ter their functional properties in a way that might re-
ﬂect an increase in surface  3 2 AChRs (Fig. 5 C, com-
pare with Fig. 1 A, inset). Similar results were found for
IMR-32 cells incubated at 29 C (unpublished data).
Transfection of  3 4 and  3 2 Cell Lines with the  5 
Subunit Had Little Effect on the Functional or 
Pharmacological Properties when Compared 
with the Parent Cell Line
 3 5 4 transfected cells exhibited pharmacological
properties that paralleled closely those of the parent
 3 4 cell line. The agonist rank order of potencies
were as follows: DMPP   Cyt   Nic   ACh, and having
EC50 values ranging from 20  M for DMPP to 83  M
for ACh (Fig. 4). The agonist efﬁcacies were nearly the
same as for the  3 4 cell line with the exception of Nic
(Table I). Previous immunoprecipitation studies of the
 3 5 4 cell line showed that 14% of the total AChRs
expressed the  5 subunit (Wang et al., 1998). This
small percentage of total AChR might not be sufﬁcient
to contribute signiﬁcantly to macroscopic currents.
This is consistent with agonist sensitivities matching
those of the  3 4 cell line. Additionally, the partial efﬁ-
cacies of both DMPP and Cyt were nearly identical for
 3 4 and  3 5 4 cells.
The  3 5 2 cell line had pharmacological proper-
ties that differed only slightly from the parent  3 2 cell
line, also. Nic was more potent than ACh on  3 5 2
cells, but the EC50 for ACh was signiﬁcantly lower than
for the  3 2 cell line (Fig. 4 and Table I). The rank or-
der of agonist potencies for the  3 5 2 cell line
(DMPP   Cyt   Nic   ACh) was essentially the same as
that for the  3 2 cell line. Also, the efﬁcacy of Nic was
greater for  3 5 2 AChRs when compared with  3 2
AChRs. The similar pharmacological properties (Table
I) between these cell lines suggest that the  5 subunit,
present in 50% of total AChRs (Wang et al., 1998), has
little impact on their agonist sensitivities. In Xenopus oo-
cytes, incorporation of the  5 subunit in  3 2 AChRs
increased both the desensitization rate and the Ca2 
permeability (Gerzanich et al., 1998).
Agonist Sensitivity and Efﬁcacy Proﬁles for  3 Cell Lines and 
IMR-32 Cells
We used the pharmacological data for AChRs in trans-
fected cells to establish prediction criteria for the pres-
ence of either  2 or  4 subunits in native human  3
AChRs that are expressed by IMR-32 cells.  3 AChRs
that are relatively insensitive to activation by ACh (i.e.,
have EC50 values greater than 100  M) and show full ef-
ﬁcacy to activation by DMPP are likely to possess  2
subunits. AChRs where Cyt has signiﬁcant efﬁcacy and
DMPP has less than full efﬁcacy are likely to contain  4
subunits. The agonist potency proﬁles found for the
 3 4 and  3 5 4 cell lines most closely resemble that
found for IMR-32 cells (Fig. 6 A). Since the  3 5 4 cell
line incorporates  5 subunit, the best match is between
IMR-32 and the  3 4 cell line.
The agonist efﬁcacy proﬁles provide additional sup-
port for the conclusion that IMR-32 cells express pre-
dominantly  3 4 AChRs (Fig. 6 B). Speciﬁcally, Cyt has
TABLE I
Comparison of Agonist Potencies for Human AChRs in IMR-32 and in 
Transfected HEK Cells
EC50 for Cell Line
Agonist IMR-32  3 4  3 5 4  3 2  3 5 2
ACh 59   6 79   8 81   15 209   26 121   18
n   1.5a n   1.5 n   1.5 n   1.7 n   1.6
(100%)b (100%) (100%) (100%) (100%)
Nic 48   7 56   15 42   5 70   6 83   12
n   1.8 n   1.6 n   1.6 n   1.2 n   1.3
(85%) (85%) (100%) (60%) (85%)
Cyt 57   3 18   1 21   3 47   34  30
n   1.5 n   2.7 n   1.9 n   1.5 n   ND
(80%) (75%) (75%) (5%) (4%)
DMPP 16   1 14   1 20   19    38    1
n   1.7 n   3.7 n   2.7 n   1.0 n   1.5
(80%) (50%) (55%) (110%) (170%)
Values for EC50 are measured in micromolar units.
aSlope.
bEfﬁcacy relative to ACh.572 Human Ganglionic AChRs
 70% efﬁcacy on the  3 4,  3 5 4, and IMR-32 cells
and  10% efﬁcacy on  3 2 and the  3 5 2 cell lines,
whereas DMPP has  100% efﬁcacy on  3 2 and
 3 5 2, but  80% efﬁcacy on  3 4,   3 5 4, and
IMR-32 cells.
Effect of Holding Potential on Agonist Properties for  3 4 
AChRs in HEK Cells
For ACh and Nic, the EC50 values were greater at  30
mV (79   8  M and 56   10  M, respectively) than at
 60 mV (43   10  M and 35   6  M, respectively)
whereas for DMPP the EC50 was little changed (15   1
 M at  30 mV and 14   1  M at  60 mV). Reducing
the holding potential also altered the efﬁcacy of Nic
and DMPP relative to ACh. The efﬁcacy of Nic peaked
between 300  M and 1 mM at  30 mV, whereas the
peak occurred at 100  M at  60 mV. For DMPP, the ef-
ﬁcacy relative to ACh increased from  50 to  65% by
depolarizing from  60 to  30 mV. Thus, the effect of
holding potential on the concentration-response rela-
tionship probably represents the impact of voltage on
channel blockade by these agonists, but could also re-
ﬂect voltage-dependent gating transitions.
Figure 6. Agonist potency and efﬁcacy pro-
ﬁles for HEK  3 cell lines and IMR-32 cells.
(A) Bar graph depicting the EC50 values from
Fig. 4 for ACh, Nic, Cyt, and DMPP on the
HEK transfected cell lines and IMR-32 cells.
The potency proﬁle for IMR-32 cells best
matches the proﬁles for the  3 4 and the
 3 4 5 cell lines. The biggest discrepancy was
seen for the potency of Cyt, which was higher
on the  4 containing transfected cell lines
than on IMR-32 cells, but the potencies of the
other three agonists matched well. (B) Bar
graph depicting the efﬁcacies of the four ago-
nists on the HEK transfected cell lines and
IMR-32 cells. The efﬁcacies of Cyt and DMPP
serve as good predictors of the   subunit iden-
tity in unknown AChRs. Thus, for IMR-32
AChRs, the efﬁcacy of both Cyt and DMPP
along with the agonist potency proﬁles lead us
to conclude that the predominant AChR in
these cells is  3 4.573 Nelson et al. 
All AChRs Exhibited Rectiﬁcation Regardless of 
Subunit Composition
Strong inward rectiﬁcation is a hallmark property of
neuronal nicotinic AChRs. It was attributed to intra-
cellular magnesium for  -BGT–sensitive currents in
rat hippocampal neurons (Alkondon and Albuquer-
que, 1994). The rectiﬁcation was removed by muta-
tions in amino acids that ﬂank the channel forming re-
gion of  3 4 and  4 2 AChRs (Haghighi and Cooper,
1998). Channel block by internal polyamines was also
reduced by these mutations (Haghighi and Cooper,
1998; Haghighi and Cooper, 2000). All of the HEK  3
AChR cell lines exhibited inward rectiﬁcation (Fig. 7).
The current-voltage relations approach reversal be-
tween 0 and  5 mV, but failed to become outward at
positive holding potentials up to  60 mV. Recordings
at  100 mV with the  3 5 2 cell line had small out-
ward currents that were  15% of the currents re-
corded at  100 mV (unpublished data). If polyamines
caused the rectiﬁcation, its persistence throughout
45–75-min recordings indicated that the large dilution
by electrode solution was insufﬁcient to relieve the
channel block. Magnesium or another ion in the elec-
trode solution could also be responsible for the rectiﬁ-
cation.
Figure 7. Current-voltage relations for  3 AChRs expressed by permanently transfected HEK cells exhibit the strong inward rectiﬁcation
that is characteristic of neuronal nicotinic AChRs. For the four  3 AChR cells lines, currents were activated by 100  M ACh at ﬁxed hold-
ing potentials spanning  80 to  60 mV. The peak amplitudes of the currents are shown plotted against holding potential after normaliz-
ing to the amplitude of the peak current measured at  80 mV. In all cases the current ceased to be inward at a holding potential between
 0 and  5 mV consistent with a nonselective cation channel. No outward currents were detected at holding potentials up to  60 mV. 574 Human Ganglionic AChRs
Desensitization Rate Reﬂects the   Subunit Identity in 
Permanently Transfected HEK Cells
The  3 2 cells exhibited desensitization that was much
faster than that found for  3 4 cells (Fig. 8). Coexpres-
sion of the  5 subunit had little effect on the desensiti-
zation of the  3 2 cell line and no effect on the  3 4
cell line. The  3 2 currents exhibited both single and
double exponential decays. For the  3 5 2 cell line,
desensitization was found to be slightly faster when
compared with the  3 2 cell line. The  3 4 cell line
and the  3 5 4 cell line had similar decay time con-
stants and both were similar to the value found for
IMR-32 AChRs.
Single-channel Properties of  3 4 AChRs Expressed in HEK 
Cells Closely Match Those of AChRs Expressed by IMR-32
The HEK  3 4 AChRs had single-channel open times
with time constants of 1.9   0.6 and 6.0   1.0 ms (Fig.
9). These values were similar to those obtained previ-
ously for  3 4 AChRs recorded from Xenopus oocytes
under identical ionic conditions (1.4   0.2 and 6.5  
0.8 ms) and similar to the values obtained for IMR-32
AChRs (1.5   0.3 and 9.2   1.2 ms; Nelson and Lind-
strom, 1999). The channel amplitudes for the HEK
 3 4 AChRs were  2.3   0.1 and  1.8   0.1 pA at
 80 mV. These amplitudes also were similar to those
for both oocyte-expressed  3 4 AChRs ( 2.3    0.1
and  1.6   0.1 pA) and IMR-32 AChRs ( 2.2   0.1
pA; Nelson and Lindstrom, 1999). These data support
the conclusion that the predominant functional AChR
in IMR-32 cells is  3 4.
Subunit Content of AChRs Expressed by IMR-32 and 
SH-SY5Y Cells
To estimate the fraction of IMR-32 AChRs that con-
tained a particular subunit, mAb-coated microwells
were used. AChRs that contained  3 (and/or  5) sub-
units (recognized by mAb 210),  2 subunits (recog-
nized by mAb 295), or  4 subunits (recognized by mAb
337), were isolated from detergent extracts. mAbs 295
or 337 were tested for their efﬁciencies in immunoiso-
lating AChRs from the transfected cells. mAb 295 (to
 2) was found to isolate 109   16% as many AChRs as
Figure 8.  3 AChRs con-
taining the  2 subunit desen-
sitize faster than those that
contain the  4 subunit. Cur-
rents evoked by ACh (300
 M) in each  3 cell line are
shown along with the ﬁt of
the current decay to either a
single or double exponential
function. Both  3 2 and
 3 5 2 AChRs exhibited de-
sensitization with a very rapid
component having time con-
stants of  100 ms. Some of
the  3 2 cell currents could
be ﬁt by double exponential
functions (5 out of 7) with
the faster component match-
ing the cells which had only a
single exponential decay as
well as a slower component
that was several hundred
milliseconds. Some of the
 3 5 2 AChR currents (7
out of 12) had a small ampli-
tude slower component. Both
the   3 4 and the  3 5 4
AChRs had currents that de-
sensitized much slower than
the  2-containing AChRs and
were always best ﬁt by single
exponential functions which
had time constants of decay
of   500 ms. All desensitiza-
tion time constants were de-
termined for currents that
were recorded at  60 mV.575 Nelson et al. 
did mAb 210 (to  3) from the  3 5 2 cell line (Table
II). mAb 337 (to  4) was found to isolate 64   2% as
many AChRs as did mAb 210 (to  3) from the  3 4
cell line (Table II). The relatively low efﬁciency of mAb
337 was conﬁrmed by saturation of immune precipita-
tion using  3 4 AChRs in extracts from Xenopus oo-
cytes where it bound 61   2% as many AChRs as mAb
210. Increasing mAb 337 concentrations to 100-fold
Figure 9. The single-channel properties for  3 4 AChRs from transfected HEK cells are nearly identical to those for  3 4 AChRs ex-
pressed in Xenopus oocytes and for IMR-32. Representative recordings of the single-channel currents for  3 4 AChRs expressed in perma-
nently transfected HEK cells are shown along with representative event amplitude and dwell time distributions. Superimposed on the
event histograms are ﬁts to either a double Gaussian function for the amplitude distribution or a double exponential function for the
open time distribution. The recordings were made in the outside-out patch conﬁguration using ACh (5  M) as agonist at -80 mV. Mean
channel open times were determined as described in materials and methods. The single-channel amplitudes and open times were
nearly identical to those for oocyte-expressed AChRs and for IMR-32 AChRs recorded under the same conditions (Nelson and Lindstrom,
1999; see preceding page).
Figure 10. Incubation in Nic increases the amount of  3 2 AChRs in IMR-32 and SH-SY5Y cells, but not  3 4 AChRs. The bar graph
represents the relative amounts of [3H]epibatidine binding to AChRs immunoisolated on mAb-coated microwells from Triton-X100 ex-
tracts of either IMR-32 or SH-SY5Y cells in the presence and absence of Nic (100  M) overnight. mAb 210 binds  3 and  5 AChRs, mAb
295 binds  2 AChRs, and mAb 337 binds  4 AChRs. For both cell lines, Nic caused an increase in binding to AChRs isolated on 210-coated
wells which was the same in magnitude as the amount of increase in binding to AChRs isolated on mAb 295-coated wells. AChRs isolated
on mAb 337-coated wells were not altered signiﬁcantly by Nic. For IMR-32 (untreated), mAb 210 isolated AChRs bound  12 fmol of
[3H]epibatidine, which corresponds to roughly 1,800 AChRs per cell when assuming two binding sites per AChR, whereas for SH-SY5Y,
mAb 210 isolated AChRs bound  3 fmol of [3H]epibatidine corresponding to  600 AChRs per cell.576 Human Ganglionic AChRs
greater than the point of saturation failed to precipi-
tate additional AChRs. This indicated that about one-
third of total  3 4 AChRs existed in which the epitope
to mAb 337 on all of the AChR’s  4 subunits is either in
the wrong conformation, obscured by another protein,
or is consistently proteolyzed.
For IMR-32 cell extracts, [3H]epibatidine binding re-
vealed that 65   5% (n   5) of AChRs bound contained
the  4 subunit when compared with those which con-
tained the  3 subunit, whereas 18   4% contained the
 2 subunit (Fig. 10 and Table II). Additionally, the
amount of AChR that could be labeled by [3H]epibati-
dine on intact IMR-32 cells (4.7   0.8 fmol per 35-mm
dish) was not signiﬁcantly different from the amount of
AChR that could immunoisolated from detergent ex-
tracts from IMR-32 cells (4.0   0.1 fmol per 35-mm
dish). Previously, we found that prolonged incubation of
another neuroblastoma cell, SH-SY5Y, in Nic increased
total  3 AChRs (Peng et al., 1997). Subsequently, we de-
termined that Nic incubation increased the amount of
AChR in  3 2-transfected cells, but had no effect on
 3 4-transfected cells, and that in SH-SY5Y,  3 2, but
not  3 4 AChRs were upregulated (Wang et al., 1998).
With this in mind, we tested Nic incubation on IMR-32
cells. Overnight Nic (100  M) treatment increased total
 3-containing AChRs by  40% (Fig. 10 and Table II),
most of which could be attributed to an increase in  2-
containing AChRs. Similar to previous ﬁndings in SH-
SY5Y cells, Nic incubation increased the amount of  3
AChRs by  80%, most of which could be attributed to
an increase in  2-containing AChRs.
The effects of Nic incubation on surface AChRs in in-
tact cells was determined also. Surface  3-containing
AChRs were measured using 125I-mAb 210 and surface
 2-containing AChRs were measured using 125I-mAb
295. In aliquots of IMR-32 cells that bound 10   0.4
fmol of 125I-mAb 210 on their surface, negligible (0.1  
0.5 fmol) 125I-mAb 295 binding was detected. Incuba-
tion in Nic (100  M overnight) did not change the
TABLE II
Relative Amounts of AChRs Containing Particular Subunits from Solid 
Phase RIAsa
Relative AChR amounts containing targeted 
subunit b
Source of AChR  3  4  2  7c
IMR-32 100 65   5 18   4 140   22
IMR-32 (after Nic)d 139   22 71   5 50   13 90   1
SH-SY5Y 100 40   6 49   2N D
SH-SY5Y (after Nic) 179   16 22   1 116   1N D
 3 4 100 64   2e ——
 3 5 2 (after Nic) 100 — 109   16 —
aAll values normalized to the amount of [3H]epibatidine bound by  3-
containing AChRs (mAb 210 isolated) for each cell line and expressed as a
percent. Typical amounts of [3H]epibatidine binding equivalent to a con-
ﬂuent 35-mm dish were as follows: 3.5 fmol for IMR-32; 1.0 fmol for SH-
SY5Y; 48 fmol for  3 4; and 38 fmol for  3 5 2 (after Nic incubation).
bmAb 210 for  3 AChRs, mAb 337 for  4 AChRs, mAb 295 for  2 AChRs,
and mAbs 306 and 319 for  7 AChRs.
cCalculated from the molar ratio of 125I- -BGT bound (13 fmol per dish
equivalent) compared with [3H]epibatidine from same extracts assuming
ﬁve  -BGT sites per  -7 AChR and two epibatidine sites per  -3 AChR.
d12-h incubation in Nic (100  M).
eReﬂects maximum efﬁciency in isolating  4-containing AChRs with mAb
337.
Figure 11. Confocal microscopy of  3 AChRs expressed by IMR-32 neuroblastoma cells and HEK cells transfected with  3 4 and  3 2
AChRs. Cells were plated, ﬁxed, permeabilized, and labeled as described in materials and methods. For each cell type, green reﬂects la-
beling of  3 subunits by Alexa 488-labeled mAb 210. For IMR-32 cells and  3 4 cells, red reﬂects secondary labeling by Alexa 568-labeled
GAM antibody against mAb 337 which bound  4 subunits. For  3 2 cells, red reﬂects secondary labeling by Alexa 594-labeled GART anti-
body against mAb 295 which bound  2 subunits. Yellow is a result of overlap in the labeling of colocalized subunits. For all cells, ToPro-3
iodide (blue) was included as a nuclear counterstain. The scale bars in the  3 4 panel represent 1, 2, 5, and 10  m, respectively.577 Nelson et al. 
amount of binding of either mAb (125I-mAb 210, 10   2
fmol; 125I-mAb 295, 0.4   0.5 fmol). For SH-SY5Y cells,
Nic incubation caused no change in the amount of 125I-
mAb 210 (4.5   1.1 fmol in control and 4.5   0.4 fmol
after Nic incubation) or 125I-mAb 295 binding to the
surface of intact SH-SY5Y cells (2.8   0.9 fmol in con-
trol and 2.7   0.8 fmol after Nic incubation). Nic incu-
bation had no effect on the properties of currents re-
corded from IMR-32 cells (Fig. 5 C), which is consistent
with the surface binding results. Thus, the increase in
 3 2 AChRs found in detergent extracts must reﬂect
an increase in intracellular AChRs.
Immunoﬂuorescence and Confocal Microscope
Confocal microscopy was used to visualize the distribu-
tion of  3 AChRs in IMR-32 neuroblastoma cells and
the  3 2 or the  3 4 transfected cells. For the trans-
fected cells, intense, clustered labeling was observed
with antibody directed against the  3 subunit. The la-
beling of  3 largely overlapped with the labeling ob-
served with antibody directed against the  4 subunit in
the  3 4 cells and the  2 subunit in the  3 2 cells
(Fig. 11). In the case of IMR-32 cells, the labeling of  3
subunit was also extensive and appeared in clusters that
overlapped with the labeling observed for antibody di-
rected at the  4 subunit (Fig. 11). Since mAb 337 (to
 4) targets a cytoplasmic epitope, all images are shown
for permeabilized cells. The clustered appearance of
the  3 label was also observed on nonpermeabilized
cells, indicating that surface AChRs were expressed in
concentrated densities (unpublished data). The  3 4
cells seem to have the largest size clusters, which proba-
bly reﬂects the fact that these cells express the greatest
levels of AChR (Wang et al., 1998).
Western Blot Analysis of Immunoisolated AChRs
AChRs from IMR-32 cells, SH-SY5Y cells, the  3 5 2 cell
line, and the  3 4 cell line were subjected to immu-
noisolation followed by Western blotting to establish
subunit associations.  3 or  2 proteins were bound with
subunit speciﬁc rat antisera raised against the  3 sub-
unit or the  2 subunit and then labeled with 125I-GART.
 4 protein was labeled directly with 125I-mAb 337. AChRs
isolated by mAb 210 from IMR-32 cells or from the
 3 5 2 transfected cell line gave strong bands when la-
beled with  3 subunit antiserum (Fig. 12). AChRs iso-
lated by mAb 295 from the  3 5 2 cell line revealed
strong labeling on Western blots with  3 or  2 (unpub-
lished data) subunit antisera. However, with IMR-32
cells, relatively weak labeling by  3 or  2 (not shown)
subunit antisera was observed for AChRs isolated by
mAb 295 when compared with  3 subunit isolated by
mAb 210, which indicated low levels of  3 subunit asso-
ciated with  2 subunit. AChRs isolated by mAb 337 resin
exhibited strong labeling from both the  3 4 cell line
and from IMR-32 cells relative to  3 subunit isolated by
mAb 210, which was consistent with most  3 subunits
forming AChRs with  4 subunits (Fig. 12). 125I-mAb 337
labeling of AChR isolated with mAb 210 resin gave
stronger signals than for AChR isolated from the same
extract by mAb 337 resin, which reﬂects the difference
in mAb efﬁciencies. These results conﬁrm that IMR-32
cells express AChRs consisting largely of  3 and  4 sub-
units and that only very low levels of the  2 subunit are
associated with the  3 subunit. Previous attempts to im-
mune isolate AChRs from IMR-32 extracts with antisera
to  4 or  6 subunits or mAb 299 (for  4) failed, reﬂect-
ing their absence (Nelson and Lindstrom, 1999).
Figure 12. Western blots of neuroblastoma AChRs compared
with AChRs expressed in permanently transfected HEK cells.
AChRs in Triton X-100 extracts were immunoisolated on mAb-
coated resin.  3-containing AChRs were isolated by mAb 210.  2-
containing AChRs were isolated by mAb 295.  4-containing
AChRs were isolated by mAb 337. Proteins were separated by elec-
trophoresis in SDS on a 12% polyacrylamide gel.  3 subunit pro-
tein was bound with rat antisera raised against the  3 subunit and
then labeled with 125I-GART.  4 subunit protein was labeled di-
rectly with 125I-mAb 337.578 Human Ganglionic AChRs
Presence of a-BGT Binding AChRs in IMR-32 Cells That Do 
Not Contain  3,  5, or  2 Subunits
IMR-32 cells have 2.6   0.6 (n   4) times more total
 -BGT binding sites than epibatidine binding sites as
measured by RIAs of detergent extracts. In a typical ex-
periment, 34   0.6 fmol of 125I- BGT binding sites of
 7-containing AChRs were immunoisolated on microw-
ells coated with mAbs 306 and mAb 319, whereas 14  
0.6 fmol of [3H]epibatidine binding sites of  3-contain-
ing AChRs were immunoisolated on mAb 210-coated
microwells from equal volumes of the same extract.
Furthermore, on the cell surface, there are 1.7   0.2
(n   3) times more binding sites for 125I- -BGT when
compared with 125I-mAb 210. Thus, it was unclear why
the functional properties failed to reﬂect the presence
of  7 containing AChRs. However, if the ratio of  -BGT
binding sites per AChR is 5:1 and the ratio of mAb 210
binding sites per AChR is 2:1, then there would be sim-
ilar amounts of  7 and  3 AChRs on the surface. For
an AChR with the rapid kinetics of a homomeric  7
AChR, this amount of AChR might not generate sufﬁ-
cient current for detection (see discussion).
It is possible that IMR-32 cells express heteromeric
 7-containing AChRs with slower kinetics that are in-
sensitive to inhibition by MLA. To detect such an AChR
we used microwells coated with either mAb 210 (to  3
or  5 subunits) or mAb 295 (to  2 subunits) and tested
for   -BGT binding. For AChRs isolated with either
mAb, no 125I- -BGT binding was detected (Fig. 13), but
wells coated with  7-selective mAbs 306 and 319 bound
40   4 fmol of 125I- -BGT from these same extracts. We
conclude that in IMR-32 cells, no  -BGT binding
AChRs are formed by the coassembly of  3,  5, or  2
subunits with the  7 AChR subunit.
We also tested the effect of overnight Nic (100  M)
treatment and nerve growth factor treatment (0.1  g/
ml for 2 d) on the amount of  7 AChR expressed by
IMR-32 cells. Nic treatment reduced slightly the total
amount of  7 AChR in IMR-32 cells, whereas NGF had
no effect (Fig. 13).
DISCUSSION
IMR-32 cells were derived from an abdominal tumor
(Tumilowicz et al., 1970) and express nicotinic AChR
subunits that are typical of ganglionic neurons:  3,  5,
 7,  2, and  4 (Gotti et al., 1997). Although several
AChR subtypes could be formed from these subunits,
our data show that the functional properties of IMR-32
AChRs resemble those of  3 4 AChRs expressed in
transfected HEK cells. No evidence was found for  3 2
or   7 AChR-mediated currents from IMR-32 cells.
 3 2 AChRs represented a small percentage of total
IMR-32  3-AChRs and were absent from the cell sur-
face. However, the amount of surface  7 AChRs ap-
peared to be similar to the amount of surface  3
AChRs. The absence of function for  3 2 or  7 AChRs
could result from differential downregulation of these
AChRs in the present developmental state of these
cells. Incubation in Nic or culturing at reduced temper-
ature increased the amount of  3 2 AChRs in IMR-32
cells, but not on their surface, in spite of the dramatic
increase in surface expression observed for  3 2
AChRs expressed in HEK cells after these treatments.
Transgenic deletions in mice of the  3,  2, and  4
subunits provided evidence that each of the subunits can
contribute to AChRs that mediate autonomic transmis-
sion (Xu et al., 1999a,b). However, the overlap in expres-
sion of   subunits and possible compensatory upregula-
tion of other subunits in knockout animals prevents iso-
lation of the specialized roles that particular  3 AChR
subtypes might play. Also, the morbidity induced by  3
deletion shows the inability of  7 AChRs alone to sustain
adequate autonomic synaptic function and provides in-
direct evidence for distinct roles played by these AChRs.
A better understanding of functional differences among
AChR subtypes is key to clarifying their roles played in
the physiology of the autonomic nervous system.
Figure 13. Only IMR-32 AChRs immunoisolated with mAbs to  7
AChR subunit bind  -BGT. The bar graph depicts the relative
amounts of 125I- -BGT binding that occurred on mAb-coated mi-
crowells after isolation of IMR-32 AChRs solubilized in Triton
X-100. Microwells coated with a combination of mAbs 306 and 319
which both recognize  7 subunits bound 35-45 fmol of 125I- -BGT,
whereas microwells coated with mAbs 210 (which recognizes  3 or
 5 subunits) or 295 (which recognizes  2 subunits) exhibited virtu-
ally no binding above background for the same AChR extracts. Ex-
tracts from IMR-32 cells that had been treated overnight with Nic
(100  M) bound slightly less 125I- -BGT than cells that were not
treated with Nic when bound on wells coated with mAbs 306/319.579 Nelson et al. 
Comparisons between the Functional and Pharmacological 
Properties of  3 AChRs Expressed by Permanently Transfected 
HEK Cells and IMR-32 Cells
The rank order of agonist potencies on IMR-32 cells
(DMPP   Nic   Cyt   ACh) was similar to reports for
ganglionic preparations from both rat and chicken
(Sargent, 1993; McGehee and Role, 1995). All of the
agonists on IMR-32 cells had nearly full efﬁcacies
(80%). Currents from IMR-32 cells exhibited strong
inward rectiﬁcation and a relatively slow rate of desensi-
tization. They were insensitive to  7-selective concen-
trations of methyllycaconitine, the potent reversible
competitive antagonist of  7-containing AChRs.
In transfected cells, the rank order of potencies for
 3 4 AChRs was DMPP   Cyt   Nic   ACh, which was
similar to the rank order for IMR-32 AChRs. Moreover,
with the exception of Cyt, the EC50 values found for ag-
onists on  3 4 AChRs were nearly identical to those
found for IMR-32 AChRs (Table I). Although the rank
order of potencies for  3 5 4 cells was also similar to
IMR-32 cells, both of these cell lines express few  5-
containing AChRs (Wang et al., 1998; Nelson and Lind-
strom, 1999). Cyt clearly differentiates between  2- and
 4-containing AChRs (Papke and Heinemann, 1994)
with   70% efﬁcacy on both  3 4 cells and IMR-32
cells, but 5% or less on  3 2 or  3 5 2 transfected
cells. Desensitization kinetics were similar between
 3 4 AChRs and IMR-32 AChRs, both of which were
much slower than the decay kinetics of  3 2 AChRs. Fi-
nally, the single-channel open times and channel am-
plitudes for the HEK-expressed  3 4 AChRs were
nearly identical to those recorded from oocytes and
very similar to those recorded from IMR-32 cells (Nel-
son and Lindstrom, 1999).
These functional data failed to eliminate the possibil-
ity that IMR-32 AChRs consist of  3 and  4 subunits
coassembled with  2 and/or  5 subunits since all possi-
ble subunit combinations were not tested in perma-
nently transfected cell lines. It is conceivable, for exam-
ple, that coassembly with  4 might mask the presence
of  2 subunits in IMR-32 AChRs. However, the present
and past molecular evidence help to dispel this con-
cern. Here, we have shown that mAb 295 (speciﬁc for
the  2 subunit) isolated  20% as many AChRs as mAb
210 (speciﬁc for  3 AChRs) from IMR-32 cell detergent
extracts and it labeled no AChRs on the cell surface
(see last paragraph of Subunit Content of AChRs... and
next section). Previously, we showed that the amount of
 5-containing AChRs in IMR-32 cells is 5% when com-
pared with the amount of  3-containing AChRs (Nel-
son and Lindstrom, 1999). These data taken together
support the conclusion from our functional studies
that the main AChR expressed by IMR-32 cells is com-
posed of  3 and  4 subunits. Furthermore, the similar-
ities in functional properties between IMR-32 AChRs
and  3 4 AChRs expressed in HEK cells illustrate two
important points: (1) the population of functional
IMR-32 AChRs is homogenous, and (2) the expression
environment does not appear to modify the functional
properties of  3 4 AChRs.
Effects of Chronic Nic Exposure on AChRs of IMR-32 
and SH-SY5Y
Previous studies demonstrated that Nic (micromolar
range) incubation increased total  3 AChRs while the
number of surface AChRs was unchanged in SH-SY5Y
cells (Peng et al., 1997) or increased in HEK cells ex-
pressing  3 2 AChRs (Wang et al., 1998). Nic upregu-
lation appears to be selective for human  3 2 AChRs
since no effect was seen on human  3 4 AChRs (Wang
et al., 1998). Nic concentrations required to upregulate
 3 2 AChRs are substantially greater than the concen-
trations that are typically achieved in serum of cigarette
smokers (Benowitz et al., 1990). Upregulation of  3 2
AChRs by high concentrations of Nic reveals a mode of
modulation that could be common among AChRs that
contain  2 subunits. The upregulation has been attrib-
uted to promoting AChR assembly coupled with re-
duced AChR turnover (Peng et al., 1997; Wang et al.,
1998). Competitive antagonists did not block upregula-
tion of  3 2 AChRs in HEK cells, but they caused low
levels of upregulation in the absence of Nic (Wang et
al., 1998). Mecamylamine, a noncompetitive antago-
nist, blocked upregulation and had no effect on
amount of AChR by itself. Clearly, a drug-induced
change in AChR conformation must occur, but the ac-
tual signaling pathway remains unclear. Nic increased
 3-containing AChRs in IMR-32 cells to a lesser extent
than those in SY-SY5Y cells. The difference in the ex-
tent of upregulation is consistent with the relative
abundance of the  2 subunit in each of the neuroblas-
toma cells. In fact,  2-containing AChRs accounted for
the majority of the AChR increase caused by Nic,
whereas  4-containing AChRs were unaffected in both
IMR-32 and SH-SY5Y cells.
No signiﬁcant surface  2 AChRs were detected by an-
tibody in IMR-32 cells, with, or without, Nic treatment.
Also, Nic caused no change in the amount of antibody
labeling of surface  3 AChRs. For SH-SY5Y, incubation
in Nic caused no signiﬁcant change in the number of
 3- or  2-containing surface AChRs. Because the total
number of AChRs expressed by these cells increased,
whereas the number of surface AChRs was unchanged
after incubation in Nic, AChRs must accumulate intra-
cellularly as suggested previously (Peng et al., 1997).
Why might  3 2 and  3 4 AChRs within gangli-
onic neurons have distinct posttranslational regulatory
mechanisms? IMR-32 and SH-SY5Y cells represent
noninnervated human ganglionic neurons in a sus-580 Human Ganglionic AChRs
pended state of maturity. The fact that they express dif-
ferent proportions of  3 2 and  3 4 AChRs and that
 3 2 levels can be selectively increased by exposure to
Nic or by reducing culture temperature shows that
mechanisms exist that speciﬁcally regulate expression
of  3 2 AChRs in ganglia at certain times of develop-
ment, stress, or activity. It is interesting that our  3 2
cell line increases surface AChRs by these treatments,
whereas the neuroblastoma cell lines do not. This
could mean that other factors such as chaperone pro-
teins or cytoskeletal-associated proteins (analogous to
rapsyn for muscle AChRs [Bloch and Froehner, 1987],
gephyrin for glycine receptors [Betz et al., 1991], or
GABA receptor–associated protein [Wang et al., 1999])
regulate surface expression, and that the presence of
these components differs between HEK and the neuro-
blastoma cells. From the knockout mice studies, it
seems that ganglionic AChRs composed of either  2 or
 4 subunits are at least minimally sufﬁcient to maintain
autonomic function. Although the simplest conclusion
would be that both of these AChRs mediate synaptic
transmission, it is more likely a reﬂection of the limita-
tions of nonconditional knockouts where compensa-
tory substitution of one subunit for the missing subunit
occurs. The signiﬁcance of the particular   subunit
that is expressed could play a role in subcellular signal-
ing that controls synaptic establishment, maintenance,
or control of expression of yet another target protein.
Speciﬁc regulation of  3 2 AChR expression could be
used to achieve these different goals. Comparisons be-
tween  3 2 and  3 4 cell lines reveal clear functional
differences between these AChRs.  3 2 AChRs are less
sensitive to activation and desensitize much more
quickly than  3 4 AChRs. Additionally,  3 AChRs con-
taining the  2 subunit have higher Ca2  permeability
than  3 AChRs containing the  4 subunit (Gerzanich
et al., 1998). It is possible that regulation of   subunit
expression is analogous to the developmental regula-
tion of   and    subunits in fetal and adult muscle
AChR, respectively. AChRs having the   subunit exhibit
smaller conductance, longer gating periods, and are
not conﬁned to the neuromuscular junction when
compared with  -containing AChRs (Hall and Sanes,
1993). This difference in functional properties reﬂects
differing needs of the muscle ﬁber at different stages of
development. Although the conductances of the  3 2
and  3 4 AChRs are not signiﬁcantly different, the gat-
ing kinetics differ signiﬁcantly with the  4-containing
AChRs exhibiting much longer open and burst times
than   3 2 AChRs (Nelson and Lindstrom, 1999).
Their unique gating properties, along with their differ-
ential regulation, allow these  3 AChR subtypes to play
specialized roles in ganglionic neurons.
Both neuroblastoma cell lines produce low amounts
of  5-containing AChRs. For IMR-32 cells,  5% of  3
AChRs contained the  5 subunit. Such low levels would
be insufﬁcient to alter macroscopic currents. However,
the same reasoning that was applied to regulated ex-
pression of  2-containing AChRs in ganglia could also
be applied to  5-containing AChRs. Considering the
impact of the  5 subunit on  3-AChR gating, conduc-
tance, and permeability (Gerzanich et al., 1998; Nelson
and Lindstrom, 1999), this would give ganglionic neu-
rons yet another way to alter nicotinic activity to ad-
dress the needs of the cell.
Expression of  7 AChRs in IMR-32 Cells with No
Detectable Function
 -BGT–sensitive currents have been reported in IMR-
32 cells previously (Gotti et al., 1995). However, be-
cause of current rundown and the relative irreversibil-
ity of  -BGT blockade, these data are difﬁcult to in-
terpret. In the present study, no IMR-32 currents
had rapid kinetics like those of an  7-type response
(Alkondon et al., 1992; Gopalakrishnan et al., 1995).
We have recorded rapidly desensitizing, Nic-activated
currents from rat hippocampal neurons that have
been attributed to  7 AChRs to validate the efﬁciency
of our application system (unpublished data). Addi-
tionally, we failed to inhibit Nic-evoked currents in
IMR-32 cells with the reversible selective  7 AChR an-
tagonist, MLA. Thus, the presence of  -BGT binding
sites measured on the cell surface in IMR-32 cells was
perplexing. However, if  7 AChRs have an  -BGT
binding site for each subunit of a homopentameric
AChR, there would be similar numbers of  7 AChRs
when compared with  3 AChRs on the cell surface.
Considering that the channel closing rate for homo-
meric  7 AChRs is at least 10,000 s 1 ([Anand et al.,
1998] compared with  150 s 1 for  3 4 AChRs [Fig.
9]) and its desensitization rate is at least 3000 s 1 (un-
published data; compared with  2 s 1 for  3 4 AChRs
[Fig. 8]) this number of  7 AChRs might fail to gener-
ate measurable current. Consistent with this reason-
ing, we estimate that there are sevenfold fewer  -BGT
binding sites in IMR-32 cells than have been reported
for transfected HEK cells from which human  7
AChRs have been characterized electrophysiologically
(Gopalakrishnan et al., 1995). However, we cannot
eliminate the possibility that the  7 AChRs expressed
by IMR-32 cells are, indeed, nonfunctional. To test for
the presence of nonhomomeric  7 AChRs with un-
expected functional properties, we immunoisolated
AChRs that contained either  3,  5, or  2 subunits,
and then attempted to label them with 125I- -BGT. No
labeling was observed on these AChRs, but  7-selective
mAbs 306 and 319 bound 40   4 fmol of 125I- -BGT
from these same extracts conﬁrming the presence of
an  7 AChR with high afﬁnity for toxin.581 Nelson et al. 
Conclusion
The physiological signiﬁcance of the potential for such
functional diversity among AChRs within individual
neurons remains unclear.  7 AChRs are highly perme-
able to Ca2 , which makes them good candidates for
triggering Ca2 -dependent events to alter expression
of proteins involved in morphological or functional
changes. The same may also be true of  3 2 AChRs as
it has been shown previously that  3 2 AChRs have
higher Ca2  permeability than  3 4 AChRs. In fact, the
more Ca2 -permeable AChRs might mediate develop-
ment and plasticity, whereas  3 4 AChRs mediate exci-
tatory synaptic transmission. In any case, it is possible
that relative amounts of AChR subtypes expressed
might vary in neurons from one ganglion to the next.
Our data indicate that IMR-32 cells express  3 4
AChRs as the predominant functional AChRs. What re-
mains to be elucidated is what mechanisms are used by
ganglionic neurons to alter the proportions of AChR
subtypes in response to changing cellular needs. Both
incubation in Nic and temperature reduction provide
useful models through which to study at least part of
these regulatory mechanisms.
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